---Terri Bernacchi, PharmD, MBA, Cambria Health Advisory Professionals, Senior Partner at Valiant Health, SME Systems
“Many Americans don't have enough information or education to make fully informed choices about healthy lifestyles, medical treatments or navigating the complex U.S. healthcare system. Poorly prepared patients can be overwhelmed by new information that follows a diagnosis. “When patients are in doctors' offices, they (might) hear 50% of what's being said and maybe their relative hears another 30%, but they walk away without 20%,” North Shore-LIJ's Vignola said.” See: Modern Healthcare Article,” Providers help patients address emotion, money, health literacy” by Melanie Evans. http://www.modernhealthcare.com/article/20131210/INFO/312129978/channeling-choice-providers-help-patients-address-emotion-money
Clearly, the Institutes of Medicine and other governmental entities and academicians are starting to study the impact of SDM in health care. More literature is coming out and the case for actively-involved patients is beginning to be better understood. But it’s a long way till we arrive at the finish line.
Terri is a Senior Partner at Valiant Health, LLC, and founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis partners. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Valiant Health colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years of experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.
A place for those of us who are aware that the next frontier of quality medical care in the US involves information-enabled consumers who are accountable and involved in their own decision making.
Thursday, December 12, 2013
Monday, October 7, 2013
Using Technology to Help People with Personal Health Decisions
---Terri Bernacchi, PharmD, MBA, Cambria Health Advisory Professionals, Senior Partner at Valiant Health, SME Systems
The internet has certainly brought to be the age of “information” which does not necessarily mean that people using the internet can make “informed decisions” about their medical care. It simply pulls up TOO much content, some of which might be relevant to the individual and some of which may actually introduce confusion which could foster misadventures and wasted resources.
The use of “Social Media” can help isolated patients feel connected to others with similar conditions or in similar predicaments, empowering them to make better medical decisions or provide their own ‘self-care’. Unfortunately, it can also introduce harm if people lack contextual insight to sift through facts versus fiction.
At this time, people have little direct access to most of their own health data, and may be handicapped with an inability to understand it, even if they had it. Thus, futurists are clamoring to develop a platform that analyzes and integrates their information with other sources of data. In the world they envision, patients will be more engaged and have access to their information via mobile applications, including access to their Electronic Health Records.
When this happens, some of the way things are currently done and the balance of power in terms of decision making will shift, creating a very different health care interaction between patient and provider.
In the future, for example, some envision that “we will see technology, artificial intelligence and predictive data analytics” incorporated as part of the decision-making process. This disruptive “voice of the computer” may not be far off. See the attached opinion piece.
Terri is a Senior Partner at Valiant Health, LLC, and founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis partners. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Valiant Health colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years of experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.
Tuesday, May 28, 2013
Hospital Studies Blows Apparent Hole in Concept of Shared Decision Making Reducing Costs
---Terri Bernacchi, PharmD, MBA, Cambria Health Advisory Professionals, Senior Partner at Valiant Health, Managing Partner at Quo Magis Partners
Answering an important question, “Does “SDM” (shared decision making) reduce cost?” was the focus of a study published by JAMA (see link below) that utilized a survey given to ~20,000 inpatients over 8 years at a single institution. They concluded that while the classic SDM concept that engaging patients in their care can help control costs and reduce utilization, SDM can actually increase lengths of stay and inpatient spending. Patients were asked to rank a preference for the statement, “I prefer to leave decisions about my care up to my doctor”. Investigators drew inferences from this as to their interest in SDM and specifically reviewed an inpatient setting. The survey data were linked with administrative data to find conclusive results.
They found that Length of Stay was longer (by 5%) and incurred cost was higher (by 6% or about $865) for people that were more inclined to want to be involved in their decision making process. One of the primary co-authors, Dr. David Melzer has been quoted by Modern Healthcare as attributing some of the lack of cost reduction to the fact that prospective payments in hospital environments already incentivize more careful resource use, and that SDM could actually increase costs.
But not so fast here. I think there may be a larger concern: conclusions about attitudes toward SDM using a generic question at the exact time a person is in an inpatient hospital setting is the exact wrong time to evaluate SDM. The principles of SDM involve the patient as an equal in the process----much has been written in the literature about the power dynamic / power imbalance between doctor and patient. This is the wrong time and the wrong way to measure its effectiveness.
In the Modern Healthcare article (requires a subscription) Melzer goes on to muse that SDM should not be thought of within a framework of cost-control, which I agree with. If the principles of SDM get misrepresented as one more way to ration resources or cut costs at the patient’s own expense, there will be no basis for trust (an essential ingredient in real SDM). SDM will fail.
(Link takes you to an abstract and not the full article: http://archinte.jamanetwork.com/article.aspx?articleid=1691765 )
I wonder what a patient would think about whether or not their doctor would see any survey response that indicates they prefer NOT to leave decisions about their care to the Doctor. In the inpatient setting, someone is making almost all decisions for you---from how much you can eat or drink to what tests are going to be done and when you can go home.
The problem lies not with posing the question but with the way in which it was measured and the environment in which it was measured. Better yet to have asked more nuanced questions BEFORE hospitalization ever occurs and gauge the avoidance of hospitalization and other procedures (and the associated cost savings) rather than the methodology of asking a patient at his /her most vulnerable time in the hospital.
Terri is a Senior Partner at Valiant Health, LLC, and founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis partners. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Valiant Health colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years of experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.Managing Partner at Quo Magis partners. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Valiant Health colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years of experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.Thursday, May 16, 2013
Shared Decision Making is the Key to Fixing Broken Health Care System
---Terri Bernacchi, PharmD, MBA, Cambria Health Advisory Professionals, Senior Partner at Valiant Health, LLC & Managing Partner at Quo Magis Partners
- “One of the welcome shifts under way in medicine is the move towards “shared decision making,” where hubris and hierarchy give way to humility and equality. Part of a wider reshaping of the roles and responsibilities of patients and professionals, the shift is challenging the long held belief that doctors know best. Rather than experts who persuade, in the new model the professionals support people in making more informed decisions about their health. But what if we take this notion of a meeting of equals seriously? Could people help professionals to make more informed decisions?”
The author, Ray Moynihan, later in the piece cites the improvement that the patient gets from reassurances from a trusted doctor as he makes his decision. One of the challenges in the current US healthcare system is the separation between the doctor and the patient in terms of who is going to decide what about the best course of action for any set of circumstances. Clearly, the clinician is the expert but non-compliance with care is in the realm of 40 to 50%, so it is fair to say that person (often at his/her own hand) does not fully realize the benefits of the clinician’s expertise simply because they choose not to heed it.
A frank and honest dialogue should begin with the very first meeting, where both the patient and the clinician set expectations and establish the rapport that becomes the basis for shared decision making. One further complication to be discussed in future posts: this takes TIME to do; under today’s health care reform environment, with pressures on reimbursements, it remains to be seen how this can occur unless the system will bear the cost burden associated with better dialogue.
Link: http://www.bmj.com/content/346/bmj.f2789Terri is a Senior Partner at Valiant Health, LLC, and founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis partners. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Valiant Health colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years of experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.
Monday, December 10, 2012
Shared Decision Making, Screening Mammograms and Quality Care
----Terri Bernacchi, PharmD, MBA, Cambria Health Advisory Professionals & Managing Partner at Quo Magis Partners
Issues in medicine typically evade grouping into “necessary” versus “unnecessary” or “good” or “bad” categories. Such is the case with the topic of screening mammography, perhaps, when viewed from the perspective of a patient or family member trying to make the most of a shrinking dollar while maximizing their health as they get older. For example, few would have argued that early diagnosis and treatment improves outcomes in most cancers.
The federal government, in fact, has endorsed screening mammograms in its 5 Star program, by paying Medicare Advantage plans explicitly for maximizing the percentage of female members between 40 and 69 who receive them every 2 years. Recently, a study in Lancet was published that concluded that for every life saved by mammography screening, 3 women will be “over-diagnosed” and ultimately treated for a cancer that may never have caused the trouble for a given person. The article suggests that screening “reduces breast cancer mortality but that some overdiagnosis occurs.”
In his book, “Overdiagnosed: Making People Sick in the Pursuit of Health”, Dr. H. Gilbert Welch, refers to some cancers as “incidentalomas” which are discovered as part of the screening we can now do enabled with-ever-more-sensitive technologies.
While I am not going to take a position on this topic, the point that I want to make is that it is confusing, at best, to the average patient. Certainly, what we “know” as indisputable fact today will be contradicted or clarified at some point in the future.
The best thing that can be done, then, for the average patient is to provide supportive guidance that stops short of being dogmatic about the use of such tests. While the quality indicators that are now driving Medicare Advantage Star ratings don’t take such nuances into account and carry real financial consequences for the plans if the member does NOT have the mammogram, the clinical and personal realities for a patient are shaded with elements that are not population-based, but very individualized. The things that motivate or demotivate a patient to receive that mammogram: fear of pain of the test or results that come from it, personal time and money, perceptions about the benefit versus the risk, and a variety of other factors. These are the real reasons a person will decide to have or not have a mammogram. And the quality question---may remain open for debate.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61216-1/fulltext
Terri is the founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis Partners. Among her current clients: a large health sciences firm serving payers, pharmaceutical and device manufacturers and other stakeholders. a small special needs health plan as a 5 Star Consultant, and several other health related clients. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Health Advisory Professional colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.
Issues in medicine typically evade grouping into “necessary” versus “unnecessary” or “good” or “bad” categories. Such is the case with the topic of screening mammography, perhaps, when viewed from the perspective of a patient or family member trying to make the most of a shrinking dollar while maximizing their health as they get older. For example, few would have argued that early diagnosis and treatment improves outcomes in most cancers.
The federal government, in fact, has endorsed screening mammograms in its 5 Star program, by paying Medicare Advantage plans explicitly for maximizing the percentage of female members between 40 and 69 who receive them every 2 years. Recently, a study in Lancet was published that concluded that for every life saved by mammography screening, 3 women will be “over-diagnosed” and ultimately treated for a cancer that may never have caused the trouble for a given person. The article suggests that screening “reduces breast cancer mortality but that some overdiagnosis occurs.”
In his book, “Overdiagnosed: Making People Sick in the Pursuit of Health”, Dr. H. Gilbert Welch, refers to some cancers as “incidentalomas” which are discovered as part of the screening we can now do enabled with-ever-more-sensitive technologies.
While I am not going to take a position on this topic, the point that I want to make is that it is confusing, at best, to the average patient. Certainly, what we “know” as indisputable fact today will be contradicted or clarified at some point in the future.
The best thing that can be done, then, for the average patient is to provide supportive guidance that stops short of being dogmatic about the use of such tests. While the quality indicators that are now driving Medicare Advantage Star ratings don’t take such nuances into account and carry real financial consequences for the plans if the member does NOT have the mammogram, the clinical and personal realities for a patient are shaded with elements that are not population-based, but very individualized. The things that motivate or demotivate a patient to receive that mammogram: fear of pain of the test or results that come from it, personal time and money, perceptions about the benefit versus the risk, and a variety of other factors. These are the real reasons a person will decide to have or not have a mammogram. And the quality question---may remain open for debate.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61216-1/fulltext
Terri is the founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis Partners. Among her current clients: a large health sciences firm serving payers, pharmaceutical and device manufacturers and other stakeholders. a small special needs health plan as a 5 Star Consultant, and several other health related clients. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Health Advisory Professional colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.
Wednesday, September 5, 2012
Shared Decision Making, Waste, & Progress
Terri Bernacchi, PharmD, MBA, Cambria Health Advisory Professionals & Managing Partner at Quo Magis Partners
The good news: there continues to be progress in the arena of shared decision making (SDM), which I believe will be one of the most important tools to achieve optimal health care outcomes and medical economics. SDM represents a deeper dialogue involving clinicians, academics, health plans, patients and family members regarding how resources are best used and expectations of care are met. If accomplished effectively, SDM will result in a more rational use of resources. More importantly, it will enable higher satisfaction on the part of all parties, but especially the patient.
The process of sharing the decision making has become its own medical expertise, representing a new field of greater study, complete with an evolving body of literature. It is the place where science, technology, social, and economic factors converge; a place where the imbalance of power between who decides and who must live with the decision meet; a place where the one who pays the bills and the one who pays the consequences must deal with the nuances. Does the decision at hand involve a clear path with easily understood risks and benefits or is it one that is fraught with vague and unknowable consequences, consuming both the patient’s limited financial resources and the system’s allocated spend, without meeting anyone’s expectations?
As I have written before, perhaps the single greatest driver of health care cost is under the umbrella of “waste”. Under this ignoble category, the labs have been ordered, prescriptions dispensed, and procedures done when the patient either did not want or comply with them, may not have understood the need or was disappointed in the results. Perhaps the whole process yielded little benefit to them personally; and the use of the system’s resources may be categorized as “wasteful”. Perhaps the physician who ordered these services did so because they were necessary; perhaps it was to cover the medical-legal checkbox. Experts comment frequently on how the elimination of “fraud” will return billions of dollars back into the system. But my take on it (without any statistics to back me up because I don’t believe there is an accurate way to measure either fraud or waste) is this: waste outweighs fraud by a factor of a hundred-fold.
One article recently caught my eye which addresses the expansion of SDM as a method of better understanding decisions and consequences, each with different points.
The first article references the differences between the physician and the patient in terms of expectations of breast cancer treatment, citing the physician’s greater sense of “reality” as compared to the patient. The study investigated “differences between patients and physicians with regard to the required efficacy of treatment and the factors influencing patients' and physicians' willingness to accept different therapeutic options.” Clearly, the patient is not on the same “reality plane” as the clinician. The study was published in Breast Cancer Res Treat. (2012 Aug 30), by FC Thiel et al, “Shared decision-making in breast cancer: discrepancy between the treatment efficacy required by patients and by physicians.”
What is most interesting to me is the last statement in the abstract which demonstrates what I believe: that each patient has unique desires and expectations, even if they have the exact same disease state, with the same odds. The uniqueness is where the opportunity for real SDM (or potential waste) comes into play. This is fruit for new dialogue and new study, and I am anxious to participate in the discussion!
(Available at the link below); “Approximately one-fifth of the patients were willing to accept treatment regimens even with marginal anticipated benefits, whereas one-third required unrealistic treatment benefits. Several influencing factors that were significantly associated with the quality rating of treatment regimens in the groups of breast cancer patients and physicians were also identified. In contrast to physicians, many breast cancer patients required treatment benefits beyond what was realistically possible, although a large group of patients were also satisfied with minimal benefits. Individual factors were also identified in both groups that significantly influence thresholds for accepting adjuvant treatment, independently of risk estimates and therapy guidelines.”
Terri is the founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis Partners. Among her current clients: a large health sciences firm serving payers, pharmaceutical and device manufacturers and other stakeholders, a small special needs health plan as a 5 Star Consultant, and several other health related clients. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Health Advisory Professional colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years experience as founder and primary servant of a health technology company which was sold to IMS Health in late 2007. She has both a BS and a PharmD in Pharmacy and an MBA.
Monday, August 13, 2012
As Rx Coupon Debate Goes On, Massachusetts Reverses Stance
----Terri Bernacchi, PharmD, MBA, Cambria Health Advisory Professionals & Managing Partner at Quo Magis Partners
I have written a number of times on the potential benefit that drug coupon programs can afford all parties in the health care exchange, but also recognize that this is a very controversial subject. Specifically, coupons programs can benefit the manufacturer who seeks to penetrate a market, a patient who is looking for a financial benefit for a drug that the physician believes is necessary, and, if done in collaboration, can help a payer manage high-cost drugs.
Recently, Massachusetts announced that it is officially lifting its long-standing (since 1988) ban on prescription drug coupon programs. Massachusetts was the last state in the country with such a ban. Certainly, the controversial methods which make these programs very attractive to the consumer continue to stir heated debate in PBM, plan, pharmaceutical manufacturer, and regulatory circles. And those parties who hope to eliminate them have to jump a significant public relations hurdle.
You can tell from the tone of the attached article that the lifting of this ban is popular with consumers. (See link: http://www.wcvb.com/health/Massachusetts-lifts-long-standing-ban-on-prescription-drug-coupons/-/9848730/15929808/-/a3k66g/-/index.html ) But coupons are an important and beneficial tool as health care reform gets underway and costs are shifted to the consumer, who will continue to act in his /her own perceived self-interest.
Case in point: The application of coupons in health care is not only about drug manufacturer but is also applied to provider services. In an article by Judy Wang Mayer, “Health Care Providers’ Use Of Groupon Stirs Up Controversy” on August 10, 2012, the author warns health care providers (dentists, physicians, surgeons) to be careful with social coupon websites. She says that although no providers have yet been disciplined by state licensing boards, it is “only a matter of time before most state boards of licensure and national professional associations take a position on the legality of these types of promotions. Until then, health care providers should be cautious and consult an attorney before signing up with a daily deal website like Groupon or Living Social.” (See link: http://www.mondaq.com/unitedstates/x/191090/Healthcare/Health+Care+Providers+Use+Of+Groupon+Stirs+Up+Controversy)
- A number of employers/unions (County and Municipal Employees District Council 37, American Federation of State, the Sergeants Benevolent Association, the Plumbers and Pipefitters Local 572, and the New England Carpenters) have sued pharmaceutical manufacturers in federal court over the presumed legality of these programs (March, 2012, see link: http://www.insurelane.com/insurance/blog/health/2012/03/08/Drug-Companies-Sued-By-Insurance-Plans-Over-Coupons.html)
- Adam Fein, PhD, of Pembroke Consulting has written considerably on this topic and is a good source of the overall topic, including this Drug Channels article from November of 2011: http://www.drugchannels.net/2011/11/pbms-launch-new-attack-on-copay-cards.html
- In the article, “Co-pay coupons: Good deal for consumers, headache for health insurance companies” by Mary Kay Jay, the author makes the case for the fact that the consumer wins while the insurance company is left to pay for a product that is many times more expensive than the generic drug they'd prefer to see be used. http://www.netquote.com/health-insurance/news/co-pay-coupons.aspx#ixzz23SMuKDYC
Terri is the founder of Cambria Health Advisory Professionals and a Managing Partner at Quo Magis Partners. Among her current clients: a large health sciences firm serving payers, pharmaceutical and device manufacturers and other stakeholders. a small special needs health plan as a 5 Star Consultant, and several other health related clients. The thoughts put forth on these postings are not necessarily reflective of the views of her employers or clients nor other Health Advisory Professional colleagues. Terri has had a varied career in health related settings including: 9 years in a clinical hospital pharmacy setting, 3 years as a pharmaceutical sales rep serving government, wholesaler, managed markets and traditional physician sales, 3 years working for the executive team of an integrated health system working with physician practices, 4 years as the director of pharmacy for a large BCBS plan, 12 years experience as founder and primary servant of a health technology company which was sold to her current employer three years ago. She has both a BS and a PharmD in Pharmacy and an MBA.
Subscribe to:
Posts (Atom)


